RESUMEN
Oleoylethanolamide (OEA) is a bioactive lipid that stimulates nuclear and G protein-coupled receptors and regulates appetite and fat metabolism. It has not previously been shown to have a role in cancer. However, a mass spectrometry-based lipidomics platform revealed the presence of high amounts of OEA in the plasma of chronic lymphocytic leukemia (CLL) patients compared with normal donors. CLL cells produced OEA and the magnitude of plasma OEA levels was related directly to the circulating leukemic cell number. OEA from CLL cells was increased by URB-597, an inhibitor of fatty acid amide hydrolase (FAAH), and decreased by inflammatory mediators that downregulate expression of N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD). These enzymes degrade and synthesize OEA, respectively. Nonphysiologic doses of OEA prevented spontaneous apoptosis of CLL cells in a receptor-independent manner that was mimicked by its free fatty acid (FFA) derivative oleate. However, OEA-containing supernatants from CLL cells induced lipolysis in adipocytes, lipid products from adipocytes protected CLL cells from cytotoxic chemotherapy, and increased levels of FFAs were found in CLL plasma that correlated with OEA. We suggest OEA is a lipolytic factor produced by CLL cells to fuel their growth with a potential role in drug resistance and cancer cachexia.
Asunto(s)
Leucemia Linfocítica Crónica de Células B/metabolismo , Ácidos Oléicos/metabolismo , Adipocitos/metabolismo , Adulto , Anciano , Amidohidrolasas/metabolismo , Estudios de Casos y Controles , Supervivencia Celular , Células Cultivadas , Endocannabinoides , Femenino , Humanos , Hidrólisis , Leucemia Linfocítica Crónica de Células B/sangre , Masculino , Persona de Mediana Edad , Ácido Oléico/metabolismo , Ácidos Oléicos/sangreRESUMEN
AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme that plays a major role in the maintenance of energy homeostasis in various organs and tissues. When activated, AMPK can induce substrate catabolism and shut down energy-consuming anabolic pathways to increase intracellular ATP availability. Even though most of these effects have been described in muscle and liver, several studies have provided compelling evidence that AMPK also plays an important role in the regulation of white adipose tissue (WAT) glucose and lipid metabolism. In fact, the effects of acute and chronic AMPK activation in the WAT induce profound changes in adiposity with important implications for the treatment of obesity and its related metabolic disorders. This review discusses the role of AMPK in the regulation of white adipocyte metabolism with respect to energy storage and release, gene expression, mitochondrial biogenesis, oxidative capacity, cell differentiation, and the potential impact on whole-body adiposity and energy homeostasis.
Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Tejido Adiposo Blanco/enzimología , Metabolismo de los Lípidos , Obesidad/enzimología , Proteínas Quinasas Activadas por AMP/genética , Adenosina Trifosfato/metabolismo , Tejido Adiposo Blanco/fisiopatología , Adiposidad , Animales , Diferenciación Celular , Activación Enzimática , Regulación de la Expresión Génica , Glucosa/metabolismo , Humanos , Recambio Mitocondrial , Obesidad/genética , Obesidad/fisiopatología , Oxidación-Reducción , Transducción de SeñalRESUMEN
Nesfatin-1 is a recently discovered anorexigen, and we first reported nesfatin-like immunoreactivity in the pancreatic ß-cells. The aim of this study was to characterize the effects of nesfatin-1 on whole-body energy homeostasis, insulin secretion, and glycemia. The in vivo effects of continuous peripheral delivery of nesfatin-1 using osmotic minipumps on food intake and substrate partitioning were examined in ad libitum-fed male Fischer 344 rats. The effects of nesfatin-1 on glucose-stimulated insulin secretion (GSIS) were examined in isolated pancreatic islets. L6 skeletal muscle cells and isolated rat adipocytes were used to assess the effects of nesfatin-1 on basal and insulin-mediated glucose uptake as well as on major steps of insulin signaling in these cells. Nesfatin-1 reduced cumulative food intake and increased spontaneous physical activity, whole-body fat oxidation, and carnitine palmitoyltransferase I mRNA expression in brown adipose tissue but did not affect uncoupling protein 1 mRNA in the brown adipose tissue. Nesfatin-1 significantly enhanced GSIS in vivo during an oral glucose tolerance test and improved insulin sensitivity. Although insulin-stimulated glucose uptake in L6 muscle cells was inhibited by nesfatin-1 pretreatment, basal and insulin-induced glucose uptake in adipocytes from nesfatin-1-treated rats was significantly increased. In agreement with our in vivo results, nesfatin-1 enhanced GSIS from isolated pancreatic islets at both normal (5.6 mM) and high (16.7 mM), but not at low (2 mM), glucose concentrations. Furthermore, nesfatin-1/nucleobindin 2 release from rat pancreatic islets was stimulated by glucose. Collectively, our data indicate that glucose-responsive nesfatin-1 regulates insulin secretion, glucose homeostasis, and whole-body energy balance in rats.
Asunto(s)
Metabolismo Energético , Glucosa/farmacología , Insulina/metabolismo , Proteínas del Tejido Nervioso/fisiología , Secuencia de Aminoácidos , Animales , Proteínas de Unión al Calcio , Proteínas de Unión al ADN , Glucosa/metabolismo , Prueba de Tolerancia a la Glucosa , Secreción de Insulina , Masculino , Datos de Secuencia Molecular , Proteínas del Tejido Nervioso/sangre , Nucleobindinas , Fosforilación , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas , Ratas Endogámicas F344RESUMEN
This study investigated the effects of obesity induced by high-fat (HF) diet on thyroid function and whole-body energy balance. To accomplish that, we assessed the effects of 8 wk of HF diet on several parameters of hypothalamus-pituitary-thyroid axis function. Serum total T(4) and T(3), rT(3), and TSH, the activity of type 1 and type 2 deiodinases in central and peripheral tissues were determined. Also, we measured in vivo energy balance, substrate partitioning, and markers of leptin resistance. Here we provide novel evidence that prolonged positive energy balance acquired by feeding a HF diet induced hyperactivation of the hypothalamus-pituitary-thyroid axis, which was characterized by 2.24-, 1.6-, and 3.7-fold elevations in hypothalamic TRH expression, thyroid iodide uptake, and serum TSH, respectively. Serum T(4) and T(3) were normal together with augmented deiodinase type 1 activity in liver (1.3-fold) and kidney (1.2-fold) and increased (1.5-fold) serum rT3 in HF rats. Despite no increase in circulating levels of T(3) and T(4), whole-body oxygen consumption was increased, and substrate metabolism was shifted toward fat oxidation in HF rats. These in vivo metabolic adjustments were mainly driven by the fat content of the diet. Furthermore, spontaneous dark cycle physical activity was reduced by 30% in rats fed a HF diet, which limited energy expenditure and favored the development of obesity. Our findings provide new insight into the endocrine and physiological mechanisms that underlie the alterations in thyroid hormone availability, energy balance, and metabolic partitioning in HF diet-induced obesity.
Asunto(s)
Grasas de la Dieta/farmacología , Metabolismo Energético/efectos de los fármacos , Yoduro Peroxidasa/metabolismo , Consumo de Oxígeno/efectos de los fármacos , Tirotropina/sangre , Tiroxina/sangre , Triyodotironina/sangre , Proteínas Quinasas Activadas por AMP/metabolismo , Tejido Adiposo/metabolismo , Animales , Western Blotting , Composición Corporal/efectos de los fármacos , Composición Corporal/genética , Prueba de Tolerancia a la Glucosa , Masculino , Reacción en Cadena de la Polimerasa , Ratas , Proteína 3 Supresora de la Señalización de Citocinas , Proteínas Supresoras de la Señalización de Citocinas/metabolismo , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/metabolismoRESUMEN
The aim of this study was to investigate the chronic effects of palmitate on fatty acid (FA) oxidation, AMPK/ACC phosphorylation/activation, intracellular lipid accumulation, and the molecular mechanisms involved in these processes in skeletal muscle cells. Exposure of L6 myotubes for 8 h to 200, 400, 600, and 800 microM of palmitate did not affect cell viability but significantly reduced FA oxidation by approximately 26.5%, approximately 43.5%, approximately 50%, and approximately 47%, respectively. Interestingly, this occurred despite significant increases in AMPK ( approximately 2.5-fold) and ACC ( approximately 3-fold) phosphorylation and in malonyl-CoA decarboxylase activity ( approximately 38-60%). Low concentrations of palmitate (50-100 microM) caused an increase ( approximately 30%) in CPT-1 activity. However, as the concentration of palmitate increased, CPT-1 activity decreased by approximately 32% after exposure for 8 h to 800 microM of palmitate. Although FA uptake was reduced ( approximately 35%) in cells exposed to increasing palmitate concentrations, intracellular lipid accumulation increased in a dose-dependent manner, reaching values approximately 2.3-, approximately 3-, and 4-fold higher than control in muscle cells exposed to 400, 600, and 800 microM palmitate, respectively. Interestingly, myotubes exposed to 400 microM of palmitate for 1 h increased basal glucose uptake and glycogen synthesis by approximately 40%. However, as time of incubation in the presence of palmitate progressed from 1 to 8 h, these increases were abolished and a time-dependent inhibition of insulin-stimulated glucose uptake ( approximately 65%) and glycogen synthesis ( approximately 30%) was observed in myotubes. These findings may help explain the dysfunctional adaptations that occur in glucose and FA metabolism in skeletal muscle under conditions of chronically elevated circulating levels of non-esterified FAs, such as in obesity and Type 2 Diabetes.
Asunto(s)
Ácidos Grasos/metabolismo , Complejos Multienzimáticos/metabolismo , Fibras Musculares Esqueléticas/enzimología , Músculo Esquelético/enzimología , Ácido Palmítico/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Quinasas Activadas por AMP , Acetil-CoA Carboxilasa/metabolismo , Animales , Carboxiliasas/metabolismo , Carnitina O-Palmitoiltransferasa/metabolismo , Línea Celular , Supervivencia Celular , Relación Dosis-Respuesta a Droga , Activación Enzimática , Glucosa/metabolismo , Glucógeno/metabolismo , Insulina/metabolismo , Fibras Musculares Esqueléticas/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Oxidación-Reducción , Ácido Palmítico/farmacología , Fosforilación , Ratas , Factores de TiempoRESUMEN
The aim of this study was to investigate the acute effects of troglitazone on several pathways of glucose and fatty acid (FA) partitioning and the molecular mechanisms involved in these processes in skeletal muscle. Exposure of L6 myotubes to troglitazone for 1 h significantly increased phosphorylation of AMPK and ACC, which was followed by approximately 30% and approximately 60% increases in palmitate oxidation and carnitine palmitoyl transferase-1 (CPT-1) activity, respectively. Troglitazone inhibited basal ( approximately 25%) and insulin-stimulated ( approximately 35%) palmitate uptake but significantly increased basal and insulin-stimulated glucose uptake by approximately 2.2- and 2.7-fold, respectively. Pharmacological inhibition of AMPK completely prevented the effects of troglitazone on palmitate oxidation and glucose uptake. Interestingly, even though troglitazone exerted an insulin sensitizing effect, it reduced basal and insulin-stimulated rates of glycogen synthesis, incorporation of glucose into lipids, and glucose oxidation to values corresponding to approximately 30%, approximately 60%, and 30% of the controls, respectively. These effects were accompanied by an increase in basal and insulin-stimulated phosphorylation of Akt(Thr308), Akt(Ser473), and GSK3alpha/beta. Troglitazone also powerfully suppressed pyruvate decarboxylation, which was followed by a significant increase in basal ( approximately 3.5-fold) and insulin-stimulated ( approximately 5.5-fold) rates of lactate production by muscle cells. In summary, we provide novel evidence that troglitazone exerts acute insulin sensitizing effects by increasing FA oxidation, reducing FA uptake, suppressing pyruvate dehydrogenase activity, and shifting glucose metabolism toward lactate production in muscle cells. These effects seem to be at least partially dependent on AMPK activation and may account for potential acute PPAR-gamma-independent anti-diabetic effects of thiazolidinediones in skeletal muscle.
Asunto(s)
Acetil-CoA Carboxilasa/metabolismo , Cromanos/farmacología , Insulina/farmacología , Complejos Multienzimáticos/metabolismo , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Complejo Piruvato Deshidrogenasa/antagonistas & inhibidores , Tiazolidinedionas/farmacología , Proteínas Quinasas Activadas por AMP , Animales , Carnitina O-Palmitoiltransferasa/metabolismo , Línea Celular , Activación Enzimática/efectos de los fármacos , Ácidos Grasos/metabolismo , Ácidos Grasos/farmacocinética , Glucosa/metabolismo , Glucógeno Sintasa Quinasa 3/metabolismo , Glucógeno Sintasa Quinasa 3 beta , Ácido Láctico/biosíntesis , Músculo Esquelético/citología , Oxidación-Reducción/efectos de los fármacos , Palmitatos/farmacocinética , Fosforilación/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/metabolismo , Pirazoles/farmacología , Pirimidinas/farmacología , Distribución Tisular/efectos de los fármacos , TroglitazonaRESUMEN
The aim of this study was to investigate the effects of 5-aminoimidasole-4-carboxamide-1-beta-d-ribofuranoside (AICAR)-induced AMP-activated protein kinase activation on glycogen metabolism in soleus (slow twitch, oxidative) and epitrochlearis (fast twitch, glycolytic) skeletal muscles. Isolated soleus and epitrochlearis muscles were incubated in the absence or presence of insulin (100 nM), AICAR (2 mM), and AICAR plus insulin. In soleus muscles exposed to insulin, glycogen synthesis and glycogen content increased 6.4- and 1.3-fold, respectively. AICAR treatment significantly suppressed ( approximately 60%) insulin-stimulated glycogen synthesis and completely prevented the increase in glycogen content induced by insulin. AICAR did not affect either basal or insulin-stimulated glucose uptake but significantly increased insulin-stimulated ( approximately 20%) lactate production in soleus muscles. Interestingly, basal glucose uptake was significantly increased ( approximately 1.4-fold) in the epitrochlearis muscle, even though neither basal nor insulin-stimulated rates of glycogen synthesis, glycogen content, and lactate production were affected by AICAR. We also report the novel evidence that AICAR markedly reduced insulin-induced Akt-Thr308 phosphorylation after 15 and 30 min exposure to insulin, which coincided with a marked reduction in glycogen synthase kinase 3 (GSK)-3alpha/beta phosphorylation. Importantly, phosphorylation of glycogen synthase was increased by AICAR treatment 45 min after insulin stimulation. Our results indicate that AICAR-induced AMP-activated protein kinase activation caused a time-dependent reduction in Akt308 phosphorylation, activation of glycogen synthase kinase-3alpha/beta, and the inactivation of glycogen synthase, which are compatible with the acute reduction in insulin-stimulated glycogen synthesis in oxidative but not glycolytic skeletal muscles.
Asunto(s)
Aminoimidazol Carboxamida/análogos & derivados , Glucógeno Sintasa Quinasa 3/fisiología , Glucógeno/biosíntesis , Insulina/farmacología , Complejos Multienzimáticos/fisiología , Músculo Esquelético/metabolismo , Proteínas Serina-Treonina Quinasas/fisiología , Proteínas Proto-Oncogénicas c-akt/fisiología , Ribonucleótidos/farmacología , Proteínas Quinasas Activadas por AMP , Aminoimidazol Carboxamida/farmacología , Animales , Glucógeno Sintasa Quinasa 3 beta , Ácido Láctico/biosíntesis , Masculino , Fosforilación , Ratas , Ratas WistarRESUMEN
The purpose of this study was to investigate the effects of long-chain fatty acids (LCFAs) on AMP-activated protein kinase (AMPK) and acetyl-coenzyme A carboxylase (ACC) phosphorylation and beta-oxidation in skeletal muscle. L6 rat skeletal muscle cells were exposed to various concentrations of palmitate (1-800 microM). Subsequently, ACC and AMPK phosphorylation and fatty acid oxidation were measured. A 2-fold increase in both AMPK and ACC phosphorylation was observed in the presence of palmitate concentrations as low as 10 microM, which was also accompanied by a significant increase in fatty acid oxidation. The effect of palmitate on AMPK and ACC phosphorylation was dose-dependent, reaching maximum increases of 3.5- and 4.5-fold, respectively. Interestingly, ACC phosphorylation was coupled with AMPK activation at palmitate concentrations ranging from 10 to 100 microM; however, at concentrations >200 microM, ACC phosphorylation and fatty acid oxidation remained high even after AMPK phosphorylation was completely prevented by the use of a selective AMPK inhibitor. This indicates that LCFAs regulate ACC activity by AMPK-dependent and -independent mechanisms, based on their abundance in skeletal muscle cells. Here, we provide novel evidence that the AMPK/ACC pathway may operate as a mechanism to sense and respond to the lipid energy charge of skeletal muscle cells.
Asunto(s)
Acetil-CoA Carboxilasa/metabolismo , Complejos Multienzimáticos/metabolismo , Fibras Musculares Esqueléticas/metabolismo , Ácido Palmítico/farmacología , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Quinasas Activadas por AMP , Adenosina Monofosfato/agonistas , Adenosina Monofosfato/metabolismo , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/farmacología , Animales , Dióxido de Carbono/metabolismo , Diferenciación Celular , Línea Celular , Relación Dosis-Respuesta a Droga , Complejos Multienzimáticos/antagonistas & inhibidores , Fibras Musculares Esqueléticas/citología , Fibras Musculares Esqueléticas/efectos de los fármacos , Oxidación-Reducción/efectos de los fármacos , Ácido Palmítico/metabolismo , Fosforilación/efectos de los fármacos , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Ratas , Ribonucleótidos/farmacologíaRESUMEN
In recent years, the adipose tissue has emerged as an important endocrine organ. It is now recognized that besides storing energy the adipocytes also secrete several bioactive peptides, collectively called adipocytokines. Among these adipocytokines, leptin, the product of the ob gene, has been extensively investigated over the last decade. Skeletal muscle and adipose tissue, two major tissues involved in the regulation of glucose and fatty acids metabolism, have been consistently demonstrated to be directly affected by leptin. By binding to its receptors located in skeletal muscle and fat cells, leptin promotes energy dissipation and prevents fatty acid accumulation and 'lipotoxicity' in these tissues. On the other hand, under conditions of peripheral leptin resistance, such as observed in obese humans, the activation of pathways involved in fatty acid oxidation may be impaired. This leads to intracellular accumulation of lipid intermediates and causes insulin resistance. This review examines the metabolic pathways that are directly activated by leptin and how it regulates glucose and fatty acids metabolism in skeletal muscle and fat tissue. Furthermore, the impact of peripheral leptin resistance in these tissues leading to dysfunctional metabolic adaptations is also discussed.
Asunto(s)
Tejido Adiposo/metabolismo , Ácidos Grasos/metabolismo , Glucosa/metabolismo , Homeostasis/fisiología , Leptina/fisiología , Músculo Esquelético/metabolismo , Animales , Humanos , Ratones , Obesidad/terapia , RatasRESUMEN
AIMS/HYPOTHESIS: The aim of this study was to determine whether adiponectin elicits glucose uptake via increased GLUT4 translocation and to investigate the metabolic fate of glucose in skeletal muscle cells treated with globular adiponectin. MATERIALS AND METHODS: Basal and insulin-stimulated 2-deoxy-D: -[(3)H]glucose uptake, cell surface myc-tagged GLUT4 content, production of (14)CO(2) by oxidation of D: -[U-(14)C]glucose and [1-(14)C]oleate, and incorporation of D: -[U-(14)C]glucose into glycogen and lactate were measured in the presence and absence of globular adiponectin. RESULTS: RT-PCR and Western blot analysis revealed that L6 cells and rat skeletal muscle cells express AdipoR1 mRNA and protein. Globular adiponectin increased both GLUT4 translocation and glucose uptake by increasing the transport V(max) of glucose without altering the K(m). Interestingly, the incorporation of D: -[U-(14)C]glucose into glycogen under basal and insulin-stimulated conditions was significantly decreased by globular adiponectin, whereas lactate production was increased. Furthermore, globular adiponectin did not affect glucose oxidation, but enhanced phosphorylation of AMP kinase and acetyl-CoA carboxylase, and fatty acid oxidation. CONCLUSIONS/INTERPRETATION: The present study is the first to show that globular adiponectin increases glucose uptake in skeletal muscle cells via GLUT4 translocation and subsequently reduces the rate of glycogen synthesis and shifts glucose metabolism toward lactate production. These effects are consistent with the increased phosphorylation of AMP kinase and acetyl-CoA carboxylase and oxidation of fatty acids induced by globular adiponectin.
Asunto(s)
Glucógeno/biosíntesis , Péptidos y Proteínas de Señalización Intercelular/farmacología , Proteínas de Transporte de Monosacáridos/metabolismo , Proteínas Musculares/metabolismo , Músculo Esquelético/metabolismo , Adenilato Quinasa/metabolismo , Adiponectina , Animales , Línea Celular , Células Cultivadas , Glucosa/metabolismo , Transportador de Glucosa de Tipo 4 , Insulina/farmacología , Lactatos/metabolismo , Músculo Esquelético/efectos de los fármacos , Ácido Oléico/metabolismo , Transporte de Proteínas , Ratas , Receptores de Adiponectina , Receptores de Superficie Celular/genética , Receptores de Superficie Celular/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
During development of Drosophila, cell proliferation and size are known to be regulated by insulin. Here we use Drosophila Kc cells to examine the molecular basis for the control of cell growth by insulin. Growing cells in the presence of insulin increased cell number above control levels at 16, 24, 48 and 72 h. We have demonstrated a novel anti-apoptotic effect of insulin (approximately 50%) in these cells, measured by caspase 3-like activity, which contributed to the increase in cell number. The anti-apoptotic effect was observed both in control cells and those in which apoptosis was induced by ultraviolet irradiation. An approximately 2-fold stimulation of bromodeoxyuridine incorporation demonstrated that insulin also increased Kc cell proliferation by stimulating new DNA synthesis. The ability of insulin to increase cell number, stimulate bromodeoxyuridine incorporation and reduce caspase 3-like activity was prevented by PD98059, which inhibits activation of the Drosophila extracellular signal regulated kinase (DERK) pathway, and was unaffected by wortmannin, an inhibitor of Drosophila phosphatidylinositol 3-kinase (DPI3K). Insulin also increased cell size approximately 2-fold and this was prevented by wortmannin and rapamycin, an inhibitor of Drosphilia target of rapamycin (DTOR). In summary, we show that DERK plays an important role in mediating the effect of insulin to reduce apoptosis and increase DNA synthesis whereas the DPI3K/DTOR/Dp70S6 kinase pathway mediates effects of insulin on cell size in Drosophila Kc cells.
Asunto(s)
Apoptosis/efectos de los fármacos , División Celular/efectos de los fármacos , Tamaño de la Célula/efectos de los fármacos , Insulina/farmacología , Androstadienos/farmacología , Animales , Bromodesoxiuridina/metabolismo , Caspasas , Células Cultivadas , ADN/biosíntesis , Drosophila , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Transducción de Señal , WortmaninaRESUMEN
Leptin directly increases the rate of exogenous glucose and fatty acids oxidation in isolated adipocytes. However, the effects of leptin on fatty acid metabolism in white adipose tIssue have not been examined in detail. Here, we report that in adipocytes incubated for 6 h in the presence of leptin (10 ng/ml), the insulin-stimulated de novo fatty acid synthesis was inhibited by 36% (P<0.05), while the exogenous oxidation of acetic and oleic acids was increased by 50% and 76% respectively. Interestingly, leptin did not alter the oxidation of intracellular fatty acids. Leptin-incubated cells presented a 16-fold increase in the incorporation of oleic acid into triglyceride (TG) and a 123% increase in the intracellular TG hydrolysis (as measured by free fatty acids release). Fatty acid-TG cycling was not affected by leptin. By employing fatty acids radiolabeled with (3)H and (14)C, we could determine the concomitant influx of fatty acids (incorporation of fatty acids into TG) and efflux of fatty acids (intracellular fatty acids oxidation and free fatty acids release) in the incubated cells. Leptin increased by 30% the net efflux of fatty acids from adipocytes. We conclude that leptin directly inhibits de novo synthesis of fatty acids and increases the release and oxidation of fatty acids in isolated rat adipocytes. These direct energy-dissipating effects of leptin may play an important role in reducing accumulation of fatty acids into TG of rat adipose cells.
Asunto(s)
Adipocitos/metabolismo , Ácidos Grasos/metabolismo , Leptina/farmacología , Ácido Acético/metabolismo , Análisis de Varianza , Animales , Células Cultivadas , Sinergismo Farmacológico , Insulina/farmacología , Líquido Intracelular/metabolismo , Masculino , Ácido Oléico/metabolismo , Oxidación-Reducción , Ratas , Ratas Wistar , Estimulación Química , Triglicéridos/metabolismoRESUMEN
Hepatic responsiveness to gluconeogenic substrates during insulin-induced hypoglycemia was investigated. For this purpose, livers were perfused with a saturating concentration of 2 mM glycerol, 5 mM L-alanine or 5 mM L-glutamine as gluconeogenic substrates. All experiments were performed 1 h after an ip injection of saline (CN group) or 1 IU/kg of insulin (IN group). The IN group showed higher (P<0.05) hepatic glucose production from glycerol, L-alanine and L-glutamine and higher (P<0.05) production of L-lactate, pyruvate and urea from L-alanine and L-glutamine. In addition, ip injection of 100 mg/kg glycerol, L-alanine and L-glutamine promoted glucose recovery. The results indicate that the hepatic capacity to produce glucose from gluconeogenic precursors was increased during insulin-induced hypoglycemia.
Asunto(s)
Animales , Masculino , Ratas , Gluconeogénesis , Hipoglucemia/metabolismo , Hígado/metabolismo , Alanina/sangre , Alanina/farmacología , Glucemia/análisis , Crioprotectores/farmacología , Gluconeogénesis/efectos de los fármacos , Glucosa/biosíntesis , Glutamina/sangre , Glutamina/farmacología , Glicerol/sangre , Glicerol/farmacología , Hipoglucemia/inducido químicamente , Insulina/efectos adversos , Ácido Láctico/biosíntesis , Hígado/efectos de los fármacos , Ácido Pirúvico/metabolismo , Ratas Wistar , Urea/metabolismoRESUMEN
The mechanism of thermoregulatory uncoupling of respiration and phosphorylation in skeletal muscles has been studied. It is found that 24 h cold exposure results in (i) a 3-fold increase in the amount of UCP3 protein in rat skeletal muscle mitochondria, and (ii) pronounced lowering of the membrane potential in isolated rat or mouse skeletal muscle mitochondria. The decrease in membrane potential is reversed by adding bovine serum albumin. Cold exposure is also found to sensitize the membrane potential to the uncoupling action of added fatty acid (laurate). After laurate addition, the recoupling effects of GDP and carboxyatractylate decrease whereas that of albumin increases in mitochondria from cold-treated rats or mice. Changes similar to those induced by cold can be initiated by the in vivo addition of thyroxine. Cold exposure does not affect energy coupling in liver mitochondria. The possible involvement of UCP3 isoforms in nucleotide-sensitive and -insensitive uncoupling is discussed.
Asunto(s)
Proteínas Portadoras/metabolismo , Frío , Músculo Esquelético/metabolismo , Animales , Regulación de la Temperatura Corporal , Proteínas Portadoras/genética , Metabolismo Energético , Membranas Intracelulares/química , Membranas Intracelulares/metabolismo , Canales Iónicos , Lauratos/farmacología , Potenciales de la Membrana , Ratones , Mitocondrias Hepáticas/metabolismo , Mitocondrias Musculares/metabolismo , Proteínas Mitocondriales , ARN Mensajero/metabolismo , Ratas , Albúmina Sérica Bovina , Tiroxina , Desacopladores/metabolismo , Proteína Desacopladora 3RESUMEN
Hepatic responsiveness to gluconeogenic substrates during insulin-induced hypoglycemia was investigated. For this purpose, livers were perfused with a saturating concentration of 2 mM glycerol, 5 mM L-alanine or 5 mM L-glutamine as gluconeogenic substrates. All experiments were performed 1 h after an ip injection of saline (CN group) or 1 IU/kg of insulin (IN group). The IN group showed higher (P<0.05) hepatic glucose production from glycerol, L-alanine and L-glutamine and higher (P<0.05) production of L-lactate, pyruvate and urea from L-alanine and L-glutamine. In addition, ip injection of 100 mg/kg glycerol, L-alanine and L-glutamine promoted glucose recovery. The results indicate that the hepatic capacity to produce glucose from gluconeogenic precursors was increased during insulin-induced hypoglycemia.
Asunto(s)
Gluconeogénesis/efectos de los fármacos , Hipoglucemia/metabolismo , Hígado/efectos de los fármacos , Alanina/sangre , Alanina/farmacología , Animales , Glucemia/análisis , Crioprotectores/farmacología , Glucosa/biosíntesis , Glutamina/sangre , Glutamina/farmacología , Glicerol/sangre , Glicerol/farmacología , Hipoglucemia/inducido químicamente , Hipoglucemiantes , Insulina , Ácido Láctico/biosíntesis , Hígado/metabolismo , Masculino , Ácido Pirúvico/metabolismo , Ratas , Ratas Wistar , Urea/metabolismoRESUMEN
There is now compelling evidence that, in addition to signaling to the central nervous system (CNS), leptin also exerts its metabolic effects acting directly on peripheral tissues. It has been demonstrated by in vivo and in vitro studies, that leptin increases glucose and fatty acid metabolism in skeletal muscle. These direct leptin effects are supported by the presence of the long form of the leptin receptor, considered to be capable of performing intracellular signaling, in peripheral tissues, including skeletal muscle. The exposure of soleus muscle to supra-physiological leptin concentrations stimulate the activity of both the pyruvate-dehydrogenase (PDH) complex and Krebs cycle. This could be due to a direct stimulation of PDH and krebs cycle by leptin or a consequence of an indirect effect of this hormone activating the mitochondrial uncoupling process. In addition, in soleus and extensor digitorum longus (EDL) muscles, leptin and insulin had opposite effects on lipid metabolism, with leptin favoring lipid oxidation and insulin favoring lipid storage as triglycerides (TG). The leptin effects on free fatty acid (FFA) oxidation were more pronounced in soleus than in EDL. The differences in response of soleus compared with that of EDL was probably due to differences in fiber type composition and metabolic characteristics. It has been demonstrated that leptin reduces the TG content of skeletal. When tissue TG content is severely depleted by hyperleptinemia in normal rats, there is a dramatic increase in insulin sensitivity. This lipopenic effect of leptin may protect from the development of insulin resistance and diabetes in animals. In humans, obesity is also associated with an increase in insulin resistance and the development of Type II diabetes, however, contrary to rats and mice, there is abundance of leptin, indicating a state of resistance to this hormone in humans. Future studies are necessary to investigate the reasons why lean subjects seem to respond properly to endogenous leptin while obese ones don't. The understanding of the putative direct leptin signaling pathway in skeletal muscle could be an important step towards the utilization of leptin or a leptin receptor agonist as therapeutic tools to treat obesity and its related metabolic disorders.
Asunto(s)
Leptina/metabolismo , Músculo Esquelético/metabolismo , Receptores de Superficie Celular , Animales , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Ácidos Grasos/metabolismo , Glucosa/metabolismo , Humanos , Insulina/metabolismo , Resistencia a la Insulina , Leptina/deficiencia , Leptina/farmacología , Obesidad/genética , Obesidad/metabolismo , Receptores de Leptina , Triglicéridos/metabolismoRESUMEN
The treatment of rats and mice with leptin causes dramatic body fat reduction and in some cases even disappearance of fat tissue. Here, we report the effects of leptin (10 and 100 ng.mL-1) on isolated rat adipocytes maintained for 15 h in culture. Leptin decreased the incorporation of acetate into total lipids by 30%. A reduction in this incorporation (42%) was still observed after the leptin-cultivated adipocytes were exposed to a supra-physiological insulin concentration (10 000 microU.mL-1). On the other hand, leptin increased acetate degradation by 69% and the maximal activity of citrate synthase by 50% in isolated adipocytes. It also increased oleate degradation by 35 and 50% at concentrations of 10 and 100 ng. mL-1, respectively. Eventually, leptin upregulated the uncoupling protein-2 (UCP2) mRNA level by 63% and had no effect on uncoupling protein-3 (UCP3) mRNA in isolated adipocytes. The upregulation of UCP2 mRNA might have contributed to the stimulation of acetate and fatty acid degradation by leptin. The peripheral effects of leptin observed in this study are in line with the general energy dissipating role postulated for this hormone and for UCP2. They suggest mechanisms by which adipocytes regulate their fat content by an autocrine pathway without the participation of the central nervous system.
Asunto(s)
Adipocitos/efectos de los fármacos , Ciclo del Ácido Cítrico/efectos de los fármacos , Ácidos Grasos/metabolismo , Leptina/farmacología , Lípidos/biosíntesis , Proteínas de Transporte de Membrana , Proteínas Mitocondriales , Biosíntesis de Proteínas , Acetatos/metabolismo , Adipocitos/metabolismo , Animales , Proteínas Portadoras/biosíntesis , Proteínas Portadoras/genética , Células Cultivadas , Citrato (si)-Sintasa/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Insulina/farmacología , Canales Iónicos , Leptina/fisiología , Malato Deshidrogenasa/metabolismo , Masculino , Ácido Oléico/metabolismo , Proteínas/genética , ARN Mensajero/biosíntesis , Ratas , Ratas Wistar , Proteína Desacopladora 2 , Proteína Desacopladora 3RESUMEN
OBJECTIVE: To investigate whether leptin interferes directly with glycogenolysis and gluconeogenesis in isolated rat hepatocytes and also in in situ rat perfused livers. ANIMALS: Male albino rats (200-250 g) were used in all experiments. MEASUREMENTS: D-glucose, L-lactate and pyruvate production. RESULTS: In the present study, no differences were found for the rates of glycolysis, as expressed by the areas under the curves, among control (24.2+5.0 mmol¿g), leptin (32.0+4.5 mmol¿g), glucagon (24.7+3.0 mmol¿g), and the leptin + glucagon (23.8+3.4 mmol¿g) groups. No difference was found for the rates of glycogenolysis between the control and the leptin perfused livers (15.2+3.9 and 15.0+3.2 mmol¿g, respectively). In the presence of glucagon, the areas under the curves for the rate of glycogenolysis rose to 108.6+3.8 mmol¿g. When leptin was combined with glucagon, the area under the curve for glycogenolysis was 43. 7+4.3 mmol¿g. In fact, leptin caused a reduction of almost 60% (P<0. 001) in the rate of glucagon-stimulated glycogenolysis. Under basal conditions, the addition of leptin (100 ng¿ml) to the incubation medium did not elicit any alteration in glucose production by isolated hepatocytes. However, in the presence of leptin, the production of glucose from glycerol (2 mM), L-lactate (2 mM). L-alanine (5 mM) and L-glutamine (5 mM) by the isolated hepatocytes was significantly reduced (30%, 30%, 23% and 25%, respectively). The rate of glucose production (glycogenolysis) by isolated hepatocytes was not different between the control and the leptin incubated groups (445.0+/-91.0 and 428.0+/-72.0 nmol¿106 cells¿h, respectively). CONCLUSION: We conclude that leptin per se does not directly affect either liver glycolysis or its glucose production, but a physiological leptin concentration is capable of acutely inducing a direct marked reduction on the rate of glucagon-stimulated glucose production in in situ rat perfused liver. Leptin is also capable of reducing glucose production from different gluconeogenic precursors in isolated hepatocytes.
Asunto(s)
Glucosa/metabolismo , Leptina/farmacología , Hígado/efectos de los fármacos , Hígado/metabolismo , Alanina/metabolismo , Animales , Glucagón/farmacología , Gluconeogénesis/efectos de los fármacos , Glutamina/metabolismo , Glicerol/metabolismo , Glucógeno/metabolismo , Ácido Láctico/metabolismo , Masculino , Ratas , Ratas WistarRESUMEN
A leptina e uma proteina produzida e secretada pelo tecido adiposo, que possui efeito supressor da ingestao alimentar agindo no hipotalamo. Recentemente, alguns autores demostraram efeitos perifericos da leptina e formularam a hipotese desta funcionar tambem como hormonio contra regulador da insulina...
Asunto(s)
Animales , Masculino , Ratas , Glucemia/metabolismo , Adipocitos/efectos de los fármacos , Músculo Esquelético/metabolismo , Tejido Adiposo/metabolismo , Ratas WistarRESUMEN
The present study examines the acute effect of leptin (50 nM) on insulin secretion and on the fractional outflow rates of 45Ca2+ and 86Rb+ from pancreatic islets isolated from male lean albino rats. Under a constant physiological glucose concentration (5.6 mM), the addition of leptin to the perifusion medium led to an increment in 45Ca2+ fractional outflow rate followed by a significant (p < 0.05) increase (26%) in the insulin release. At low glucose concentration (2.8 mM), leptin also elicited a significant (p < 0.05; 50-60%) increase in insulin secretion. However, under supraphysiological (16.7 mM) glucose concentration, the rapid first-phase insulin secretion response was abolished. At low glucose levels, islets perifused in the presence of leptin presented a lower 86Rb+ fractional outflow rate compared with perifused controls. In contrast, when glucose was switched to 16.7 mM, compared with controls, a slight increase in the 86Rb+ fractional outflow rate was observed instead. These in vitro data provide evidence that, by changing K+ fluxes, leptin might modulate insulin secretion from pancreatic islets.